# GYRE THERAPEUTICS, INC. > Alpha governed public record. Unknown, unavailable, and unpublished values are never inferred as zero. ## Record | Field | Value | | --- | --- | | Representation | alpha-profile-markdown-v4 | | Protocol | Alpha Governance Facts Protocol 0.1 | | Schema | alpha.governance.entity.public.v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | Governance record representation | alpha-governance-record-v2 | | Canonical entity | alpha:company:07e067a8-43a3-4e49-a390-254524565636 | | Entity type | Company | | Canonical URL | https://registry.alpha.ac/companies/gyre-therapeutics-inc | | Publication | PUBLISHED | | Verification | source_reported | | Verification schema | alpha-verification-states-v1 | | Ownership | unclaimed | | Published claims | 22 | | Claims under review | 1 | | Evidence records | 8 | | Conflicts | 0 | | Conflicts in internal review | 0 | | Observed | 2026-10-19T04:46:31.170154+00:00 | | Last reviewed | 2026-10-19T04:46:31.170154+00:00 | ## Identity - Legal name: GYRE THERAPEUTICS, INC. - Display name: GYRE THERAPEUTICS, INC. ## Alpha Governance Record | Field | Value | | --- | --- | | Governance Record schema | alpha-governance-record-v2 | | Ontology | alpha-governance-ontology-v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | As of | 2026-10-19T09:47:15.022562+00:00 | | Completeness | 0.409 | | Record Quality | 0.848 | | Directors | 8 | | Committees | 4 | | Governance events | 18 | | Entity class | public_company | ## Section coverage | Section | State | | --- | --- | | identity | PUBLISHED | | corporate_structure | NOT_REVIEWED | | board | PUBLISHED | | committees | PUBLISHED | | leadership | PUBLISHED | | ownership | NOT_REVIEWED | | financials | NOT_REVIEWED | | capital_structure | PUBLISHED | | compensation | NOT_REVIEWED | | governance | NOT_REVIEWED | | shareholder_governance | NOT_REVIEWED | | audit | NOT_REVIEWED | | legal | NOT_REVIEWED | | risk | NOT_REVIEWED | | cyber | NOT_REVIEWED | | ai_governance | NOT_REVIEWED | | agent_governance | RESTRICTED | | markets_external | NOT_REVIEWED | | events | PUBLISHED | | relationships | PUBLISHED | | assessments | PUBLISHED | | evidence | PUBLISHED | ## Board - David M. Epstein, Ph.D.: Director. Status: current. Independent: true. Since: 2024-01-01. claim_id=alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:5 - Gordon Carmichael, Ph.D.: Director. Status: current. Independent: true. Since: 2023-01-01. claim_id=alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:6 - Han Ying, Ph.D.: Director. Status: current. Independent: false. Since: 2023-01-01. claim_id=alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:7 - Ping Zhang: Director. Status: current. Independent: false. Since: 2025-01-01. Committees: Nominating and Governance (member). claim_id=alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:8 - Renate Parry, Ph.D.: Director. Status: current. Independent: true. Since: 2023-01-01. claim_id=alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:9 - Rodney Nussbaum: Director. Status: current. Independent: true. Since: 2024-01-01. Committees: Audit (chair); Audit · Chair (member). claim_id=alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:10 - Songjiang Ma: Director. Status: current. Independent: false. Since: 2023-01-01. claim_id=alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:11 - Thomas Eastling: Director. Status: current. Independent: false. Since: 2023-01-01. Committees: Nominating and Governance (chair); Nominating and Governance · Chair (member). claim_id=alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:12 ## Committees - Audit (audit). Chair: Rodney Nussbaum. Members: Rodney Nussbaum (chair, current). committee_id=alpha:committee:gyre-therapeutics-inc:audit - Audit · Chair (audit). Chair: NOT_PUBLISHED. Members: Rodney Nussbaum (member, current). committee_id=alpha:committee:gyre-therapeutics-inc:audit-chair - Nominating and Governance (nominating_governance). Chair: Thomas Eastling. Members: Thomas Eastling (chair, current); Ping Zhang (member, current). committee_id=alpha:committee:gyre-therapeutics-inc:nominating-and-governance - Nominating and Governance · Chair (nominating_governance). Chair: NOT_PUBLISHED. Members: Thomas Eastling (member, current). committee_id=alpha:committee:gyre-therapeutics-inc:nominating-and-governance-chair ## Executive leadership - Han Ying, Ph.D.: Senior Vice President, Science. Status: current. claim_id=alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:13 - Ping Zhang: Chief Executive Officer [CEO]. Status: current. claim_id=alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:14 - Ruoyu Chen: Chief Financial Officer [CFO]. Status: current. claim_id=alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:15 - Songjiang Ma: President [PRESIDENT]. Status: current. claim_id=alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:16 - Weiguo Ye: Chief Operating Officer [COO]. Status: current. claim_id=alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:17 ## Governance events - EXECUTIVE_APPOINTED: Han Ying, Ph.D. executive of GYRE THERAPEUTICS, INC., effective 2026-04-27. Effective: 2026-04-27. Detected: 2026-10-19T04:46:31.170154+00:00. event_id=alpha:event:transition:wzhlne1f1xk74 - CEO_CHANGED: Ping Zhang executive of GYRE THERAPEUTICS, INC., effective 2026-04-27. Effective: 2026-04-27. Detected: 2026-10-19T04:46:31.170154+00:00. event_id=alpha:event:transition:10o0oqh1iv72d3 - CFO_CHANGED: Ruoyu Chen executive of GYRE THERAPEUTICS, INC., effective 2026-04-27. Effective: 2026-04-27. Detected: 2026-10-19T04:46:31.170154+00:00. event_id=alpha:event:transition:18j11yb1shp2e7 - EXECUTIVE_APPOINTED: Songjiang Ma executive of GYRE THERAPEUTICS, INC., effective 2026-04-27. Effective: 2026-04-27. Detected: 2026-10-19T04:46:31.170154+00:00. event_id=alpha:event:transition:bt9xrs2npyza - EXECUTIVE_APPOINTED: Weiguo Ye executive of GYRE THERAPEUTICS, INC., effective 2026-04-27. Effective: 2026-04-27. Detected: 2026-10-19T04:46:31.170154+00:00. event_id=alpha:event:transition:1m7mtjyh7l0cq - DIRECTOR_APPOINTED: Ping Zhang seat on GYRE THERAPEUTICS, INC., effective 2025-01-01. Effective: 2025-01-01. Detected: 2026-10-19T04:46:31.170154+00:00. event_id=alpha:event:transition:hl1furexzj5t - COMMITTEE_MEMBER_ADDED: Ping Zhang member of Nominating and Governance, effective 2025-01-01. Effective: 2025-01-01. Detected: 2026-10-19T04:46:31.170154+00:00. event_id=alpha:event:transition:1nl0tp2g59nhi - DIRECTOR_APPOINTED: David M. Epstein, Ph.D. seat on GYRE THERAPEUTICS, INC., effective 2024-01-01. Effective: 2024-01-01. Detected: 2026-10-19T04:46:31.170154+00:00. event_id=alpha:event:transition:ntolf5hh1kbt - DIRECTOR_APPOINTED: Rodney Nussbaum seat on GYRE THERAPEUTICS, INC., effective 2024-01-01. Effective: 2024-01-01. Detected: 2026-10-19T04:46:31.170154+00:00. event_id=alpha:event:transition:5t4mr91hwy8vp - COMMITTEE_CREATED: Audit · Chair committee of GYRE THERAPEUTICS, INC., effective 2024-01-01. Effective: 2024-01-01. Detected: 2026-10-19T04:46:31.170154+00:00. event_id=alpha:event:transition:px3izbwc9fwp - COMMITTEE_MEMBER_ADDED: Rodney Nussbaum member of Audit · Chair, effective 2024-01-01. Effective: 2024-01-01. Detected: 2026-10-19T04:46:31.170154+00:00. event_id=alpha:event:transition:14c74hr14vhee3 - DIRECTOR_APPOINTED: Gordon Carmichael, Ph.D. seat on GYRE THERAPEUTICS, INC., effective 2023-01-01. Effective: 2023-01-01. Detected: 2026-10-19T04:46:31.170154+00:00. event_id=alpha:event:transition:9bedwb16uyott - DIRECTOR_APPOINTED: Han Ying, Ph.D. seat on GYRE THERAPEUTICS, INC., effective 2023-01-01. Effective: 2023-01-01. Detected: 2026-10-19T04:46:31.170154+00:00. event_id=alpha:event:transition:v9bca04veyh0 - DIRECTOR_APPOINTED: Renate Parry, Ph.D. seat on GYRE THERAPEUTICS, INC., effective 2023-01-01. Effective: 2023-01-01. Detected: 2026-10-19T04:46:31.170154+00:00. event_id=alpha:event:transition:hmk1hs1d4ay7q - DIRECTOR_APPOINTED: Songjiang Ma seat on GYRE THERAPEUTICS, INC., effective 2023-01-01. Effective: 2023-01-01. Detected: 2026-10-19T04:46:31.170154+00:00. event_id=alpha:event:transition:pej6glkewckn - DIRECTOR_APPOINTED: Thomas Eastling seat on GYRE THERAPEUTICS, INC., effective 2023-01-01. Effective: 2023-01-01. Detected: 2026-10-19T04:46:31.170154+00:00. event_id=alpha:event:transition:1we55cuf2msp8 - COMMITTEE_CREATED: Nominating and Governance · Chair committee of GYRE THERAPEUTICS, INC., effective 2023-01-01. Effective: 2023-01-01. Detected: 2026-10-19T04:46:31.170154+00:00. event_id=alpha:event:transition:x0ipc21go7y90 - COMMITTEE_MEMBER_ADDED: Thomas Eastling member of Nominating and Governance · Chair, effective 2023-01-01. Effective: 2023-01-01. Detected: 2026-10-19T04:46:31.170154+00:00. event_id=alpha:event:transition:19q3jte1e5o7vg ## Scoped resources - `alpha://company/gyre-therapeutics-inc` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record - `alpha://company/gyre-therapeutics-inc/identity` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=identity - `alpha://company/gyre-therapeutics-inc/corporate-structure` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=corporate-structure - `alpha://company/gyre-therapeutics-inc/board` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=board - `alpha://company/gyre-therapeutics-inc/committees` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=committees - `alpha://company/gyre-therapeutics-inc/leadership` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=leadership - `alpha://company/gyre-therapeutics-inc/ownership` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=ownership - `alpha://company/gyre-therapeutics-inc/financials` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=financials - `alpha://company/gyre-therapeutics-inc/capital-structure` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=capital-structure - `alpha://company/gyre-therapeutics-inc/compensation` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=compensation - `alpha://company/gyre-therapeutics-inc/governance` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=governance - `alpha://company/gyre-therapeutics-inc/shareholder-governance` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=shareholder-governance - `alpha://company/gyre-therapeutics-inc/audit` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=audit - `alpha://company/gyre-therapeutics-inc/legal` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=legal - `alpha://company/gyre-therapeutics-inc/risk` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=risk - `alpha://company/gyre-therapeutics-inc/cyber` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=cyber - `alpha://company/gyre-therapeutics-inc/ai-governance` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=ai-governance - `alpha://company/gyre-therapeutics-inc/agents` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=agents - `alpha://company/gyre-therapeutics-inc/ecosystem` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=ecosystem - `alpha://company/gyre-therapeutics-inc/events` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=events - `alpha://company/gyre-therapeutics-inc/relationships` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=relationships - `alpha://company/gyre-therapeutics-inc/assessments` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=assessments - `alpha://company/gyre-therapeutics-inc/evidence` (contract): https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record§ion=evidence ## Role modules - NOT_ASSERTED ## Attention - NO_RECORDS_FOUND ## Committee data - Claim alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:committee_appointment:19: `{"kind":"committee_appointment","original_name":"Audit","category":"audit","role":"chair","person":{"alpha_id":"alpha:person:rodney-nussbaum","name":"Rodney Nussbaum"},"source_id":"board_seats"}` - Claim alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:committee_appointment:21: `{"kind":"committee_appointment","original_name":"Nominating and Governance","category":"nominating_governance","role":"chair","person":{"alpha_id":"alpha:person:thomas-eastling","name":"Thomas Eastling"},"source_id":"board_seats"}` - Claim alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:committee_appointment:22: `{"kind":"committee_appointment","original_name":"Nominating and Governance","category":"nominating_governance","role":"member","person":{"alpha_id":"alpha:person:ping-zhang","name":"Ping Zhang"},"source_id":"board_seats"}` ## Leadership - David M. Epstein, Ph.D.: Director. Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:5. Valid from: 2024-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:2c7e2e1f23e140f689a979521c8e4448116c2d8d4ec22dbaca22a68f99bf0523. - Gordon Carmichael, Ph.D.: Director. Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:6. Valid from: 2023-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:2c7e2e1f23e140f689a979521c8e4448116c2d8d4ec22dbaca22a68f99bf0523. - Han Ying, Ph.D.: Director. Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:7. Valid from: 2023-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:2c7e2e1f23e140f689a979521c8e4448116c2d8d4ec22dbaca22a68f99bf0523. - Ping Zhang: Director, Nominating and Governance. Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:8. Valid from: 2025-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:2c7e2e1f23e140f689a979521c8e4448116c2d8d4ec22dbaca22a68f99bf0523. - Renate Parry, Ph.D.: Director. Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:9. Valid from: 2023-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:2c7e2e1f23e140f689a979521c8e4448116c2d8d4ec22dbaca22a68f99bf0523. - Rodney Nussbaum: Director, Audit · Chair. Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:10. Valid from: 2024-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:2c7e2e1f23e140f689a979521c8e4448116c2d8d4ec22dbaca22a68f99bf0523. - Songjiang Ma: Director. Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:11. Valid from: 2023-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:2c7e2e1f23e140f689a979521c8e4448116c2d8d4ec22dbaca22a68f99bf0523. - Thomas Eastling: Director, Nominating and Governance · Chair. Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:12. Valid from: 2023-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:2c7e2e1f23e140f689a979521c8e4448116c2d8d4ec22dbaca22a68f99bf0523. - Han Ying, Ph.D.: Senior Vice President, Science. Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:13. Valid from: 2026-04-27. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:5318b816495da93c437151a13aa393a3b17bbc9976cd78762b4a5cb1e6cfb46c. - Ping Zhang: Chief Executive Officer. Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:14. Valid from: 2026-04-27. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:e54424b984bc05d8bfc80a77412b10927f2b89dcc0900d7e680e12c7a3c17bb9. - Ruoyu Chen: Chief Financial Officer. Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:15. Valid from: 2026-04-27. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:669cdb5b627177af8696f28464136346920dfaf3f69db870d2d97f3b3e6f69c8. - Songjiang Ma: President. Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:16. Valid from: 2026-04-27. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:0586a36ab744a7968768f60217453542ddbbc4e74870299032b7ad69ece93a53. - Weiguo Ye: Chief Operating Officer. Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:leadership_role:17. Valid from: 2026-04-27. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:f105aa789bf5ea7313dbe076a52c63d3bf9de2b925e6bb6aa0e99eeb17cad199. ## Roles - PUBLISHED ## Governance - NOT_ASSERTED ## Board committees - Audit: Chair Rodney Nussbaum; Members Rodney Nussbaum (Chair). Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:committee_record:18. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1d7bbbcc2acaf2ee9bd6596dd96ebdf8d1cdce7ea78f8eb8dbd38117a04a833b. - Nominating and Governance: Chair Thomas Eastling; Members Thomas Eastling (Chair); Ping Zhang. Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:committee_record:20. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1d7bbbcc2acaf2ee9bd6596dd96ebdf8d1cdce7ea78f8eb8dbd38117a04a833b. ## Financials - NOT_ASSERTED ## Workforce - NOT_ASSERTED ## Market and index context - PUBLISHED ## Legal Name - GYRE THERAPEUTICS, INC.. Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:legal_name:1. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:4673c260d9774dbd229a0fe56bc1c9238bba4a7d9d02aebf4a6953028f42decb. ## Entity Status - Public listing published. Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:entity_status:3. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:4673c260d9774dbd229a0fe56bc1c9238bba4a7d9d02aebf4a6953028f42decb. ## Published Fact - US. Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:published_fact:4. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:4673c260d9774dbd229a0fe56bc1c9238bba4a7d9d02aebf4a6953028f42decb. ## Committee Appointment - Rodney Nussbaum: chair, Audit. Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:committee_appointment:19. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1d7bbbcc2acaf2ee9bd6596dd96ebdf8d1cdce7ea78f8eb8dbd38117a04a833b. - Thomas Eastling: chair, Nominating and Governance. Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:committee_appointment:21. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1d7bbbcc2acaf2ee9bd6596dd96ebdf8d1cdce7ea78f8eb8dbd38117a04a833b. - Ping Zhang: member, Nominating and Governance. Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:committee_appointment:22. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1d7bbbcc2acaf2ee9bd6596dd96ebdf8d1cdce7ea78f8eb8dbd38117a04a833b. ## Security Listing - GYRE (NASDAQ). Claim: alpha:claim:company:07e067a8-43a3-4e49-a390-254524565636:security_listing:23. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:4673c260d9774dbd229a0fe56bc1c9238bba4a7d9d02aebf4a6953028f42decb. ## Coverage states | Field | Value | | --- | --- | | Identity | PUBLISHED | | Business | PUBLISHED | | Leadership | PUBLISHED | | Board and committees | PUBLISHED | | Governance | NOT_ASSERTED | | Financials | NOT_ASSERTED | | Workforce | NOT_ASSERTED | | Ownership | NOT_ASSERTED | | Ratings | NOT_PUBLISHED | | Market and index context | PUBLISHED | ## Public sources - alpha:projection-evidence:4673c260d9774dbd229a0fe56bc1c9238bba4a7d9d02aebf4a6953028f42decb: [Alpha canonical company public projection](https://www.alpha.ac/api/public/companies/gyre-therapeutics-inc). - alpha:projection-evidence:document:2c7e2e1f23e140f689a979521c8e4448116c2d8d4ec22dbaca22a68f99bf0523: [GYRE THERAPEUTICS, INC. DEF 14A 2025-04-21](https://www.sec.gov/Archives/edgar/data/1124105/000114036125014779/ny20044429x1_def14a.htm). - alpha:projection-evidence:document:5318b816495da93c437151a13aa393a3b17bbc9976cd78762b4a5cb1e6cfb46c: [GYRE DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1124105/000114036126017124/ny20063852x3_def14a.htm). - alpha:projection-evidence:document:e54424b984bc05d8bfc80a77412b10927f2b89dcc0900d7e680e12c7a3c17bb9: [GYRE DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1124105/000114036126017124/ny20063852x3_def14a.htm). - alpha:projection-evidence:document:669cdb5b627177af8696f28464136346920dfaf3f69db870d2d97f3b3e6f69c8: [GYRE DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1124105/000114036126017124/ny20063852x3_def14a.htm). - alpha:projection-evidence:document:0586a36ab744a7968768f60217453542ddbbc4e74870299032b7ad69ece93a53: [GYRE DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1124105/000114036126017124/ny20063852x3_def14a.htm). - alpha:projection-evidence:document:f105aa789bf5ea7313dbe076a52c63d3bf9de2b925e6bb6aa0e99eeb17cad199: [GYRE DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1124105/000114036126017124/ny20063852x3_def14a.htm). - alpha:projection-evidence:1d7bbbcc2acaf2ee9bd6596dd96ebdf8d1cdce7ea78f8eb8dbd38117a04a833b: [Audit](https://www.sec.gov/Archives/edgar/data/1124105/000114036125014779/ny20044429x1_def14a.htm). ## Rights | Field | Value | | --- | --- | | public_retrieval | allowed | | agent_retrieval | allowed | | redistribution | not_granted | | model_training | not_granted | | commercial_use | not_specified | | relationship_pathfinding | not_granted | | direct_contact | not_granted | ## Limitations - Absence of a leadership role, committee, or disclosure is not evidence that it does not exist. - Only explicitly published canonical company identity and current confirmed public roles are included. - Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist. - Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights. - This Company Profile is an identity and evidence record, not an Alpha rating. ## Alternate representations - [Canonical profile](https://registry.alpha.ac/companies/gyre-therapeutics-inc) - [Public Markdown](https://registry.alpha.ac/companies/gyre-therapeutics-inc.md) - [Public JSON](https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=record) - [JSON-LD](https://registry.alpha.ac/api/public/companies/gyre-therapeutics-inc?format=jsonld) - MCP resource: `alpha://companies/gyre-therapeutics-inc` at https://mcp.alpha.ac/mcp ## Connected governance records Only explicitly published, rights-cleared records. Missing records do not establish absence, safety, or complete coverage. ## Critical-risk oversight Snapshot as of 2026-10-19T09:47:14.809793+00:00; recorded 2026-10-19T09:47:14.809793+00:00. Every published assignment for this snapshot is listed. Only explicitly reviewed, rights-cleared assignments in effect on the as-of date, in the company's own wording. An assignment shows where oversight is placed, not whether it is effective. Missing records do not establish absence.